Nikolas Plevris
YOU?
Author Swipe
View article: Twenty‐Year Trends in Colectomy Rates and Advanced Therapy Prescribing in Lothian, Scotland
Twenty‐Year Trends in Colectomy Rates and Advanced Therapy Prescribing in Lothian, Scotland Open
Background The impact of advanced therapy prescribing on colectomy rates in ulcerative colitis (UC) is unknown with conflicting published evidence. Aim To describe advanced therapy prescribing trends and colectomy rates for patients with U…
View article: OP07 Psychosocial factors are associated with risk of flare in IBD; results from the PREdiCCt study
OP07 Psychosocial factors are associated with risk of flare in IBD; results from the PREdiCCt study Open
Background Patients with IBD suffer a high prevalence of psychological disorders. The impact of psychosocial factors on the risk of a disease flare is unknown. We aimed to assess associations between psychosocial factors and disease flare.…
View article: OP19 Pre- and Post-diagnostic Metabolomic Biomarker Profiling of Over 700,000 Individuals in Three National Biobanks Enables Prediction of Inflammatory Bowel Disease Onset and Complications
OP19 Pre- and Post-diagnostic Metabolomic Biomarker Profiling of Over 700,000 Individuals in Three National Biobanks Enables Prediction of Inflammatory Bowel Disease Onset and Complications Open
Background We currently lack sensitive and specific prognostic biomarkers of inflammatory bowel disease (IBD) onset and severity. In three large, population-scale cohorts, we investigated metabolomic biomarkers for predicting disease onset…
View article: P0626 One year outcomes of upadacitinib in Crohn’s disease in a large real-world cohort
P0626 One year outcomes of upadacitinib in Crohn’s disease in a large real-world cohort Open
Background Upadacitinib (UPA) was approved in April 2023 for the treatment of moderate and severe active Crohn’s disease (CD) by European and UK regulators (EMA / MHRA). Current real-world datasets are limited by small size and short follo…
View article: Tofacitinib Versus Vedolizumab Among Bio-naive Patients With Ulcerative Colitis: A Real-World Propensity-Weighted Comparison
Tofacitinib Versus Vedolizumab Among Bio-naive Patients With Ulcerative Colitis: A Real-World Propensity-Weighted Comparison Open
Background and Aims Over the last decade, treatment options for moderate-to-severe ulcerative colitis (UC) have expanded. However, comparative studies between these agents are limited, especially among biologic-naive patients. We aimed to …
View article: Large-scale clustering of longitudinal faecal calprotectin and C-reactive protein profiles in inflammatory bowel disease
Large-scale clustering of longitudinal faecal calprotectin and C-reactive protein profiles in inflammatory bowel disease Open
Background Crohn’s disease (CD) and ulcerative colitis (UC) are highly heterogeneous, dynamic and unpredictable, with a marked disconnect between symptoms and intestinal inflammation. Objective We aimed to describe latent disease heterogen…
View article: Real-world effectiveness of upadacitinib in Crohn’s disease: a UK multicentre retrospective cohort study
Real-world effectiveness of upadacitinib in Crohn’s disease: a UK multicentre retrospective cohort study Open
Background Upadacitinib is a Janus kinase inhibitor, which has recently been approved for treating Crohn’s disease. There are limited real-world studies on the outcomes of upadacitinib in Crohn’s disease. Objective Our aim was to evaluate …
View article: P860 Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitis - a six-year follow-up study
P860 Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitis - a six-year follow-up study Open
Background Long-term vedolizumab (VDZ) outcomes in real-world cohorts have been largely limited to 1-year follow-up, with few bio-naïve patients or objective markers of inflammation assessed. We aimed to assess factors affecting VDZ persis…
View article: DOP17 Tofacitinib versus Vedolizumab Among Bio-naïve Patients With Ulcerative Colitis: A Real-World Propensity-Weighted Comparison
DOP17 Tofacitinib versus Vedolizumab Among Bio-naïve Patients With Ulcerative Colitis: A Real-World Propensity-Weighted Comparison Open
Background Over the last decade, treatment options for moderate-to-severe ulcerative colitis (UC) have expanded. However, comparative studies between these agents are limited, especially among biologic naïve patients. There are sparse data…
View article: Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitis
Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitis Open
Background: Long-term vedolizumab (VDZ) outcomes in real-world cohorts have been largely limited to 1-year follow-up, with few bio-naïve patients or objective markers of inflammation assessed. Objectives: We aimed to assess factors affecti…
View article: P823 Real-world effectiveness of upadacitinib in Crohn's disease; a UK multicentre retrospective cohort study
P823 Real-world effectiveness of upadacitinib in Crohn's disease; a UK multicentre retrospective cohort study Open
Background Upadacitinib is a Janus kinase inhibitor which has recently been approved for the treatment of Crohn’s disease. There are limited real-world studies on the outcomes of upadacitinib in Crohn’s disease. Our aim was to evaluate the…
View article: Real-world Cohort Study on the Effectiveness and Safety of Filgotinib Use in Ulcerative Colitis
Real-world Cohort Study on the Effectiveness and Safety of Filgotinib Use in Ulcerative Colitis Open
Background Filgotinib is a small molecule with preferential inhibition of Janus kinase type 1, approved for the treatment of ulcerative colitis in Scotland in May 2022. We present the first real-world experience on its use in clinical prac…
View article: Validation of the ACE [Albumin, CRP, and Endoscopy] Index in Acute Colitis: Analysis of the CONSTRUCT dataset
Validation of the ACE [Albumin, CRP, and Endoscopy] Index in Acute Colitis: Analysis of the CONSTRUCT dataset Open
Background and Aims In 2020 we reported the ACE Index in acute colitis which used biochemical and endoscopic parameters to predict steroid non-response on admission in patients with acute ulcerative colitis [UC]. We aimed to validate the A…
View article: Longitudinal Fecal Calprotectin Profiles Characterize Disease Course Heterogeneity in Crohn’s Disease
Longitudinal Fecal Calprotectin Profiles Characterize Disease Course Heterogeneity in Crohn’s Disease Open
Our analysis demonstrates a novel approach to characterizing the heterogeneity of Crohn's disease by using fecal calprotectin. The group profiles do not simply reflect different treatment regimens and do not mirror classical disease progre…
View article: Multiple infliximab biosimilar switches appear to be safe and effective in a real‐world inflammatory bowel disease cohort
Multiple infliximab biosimilar switches appear to be safe and effective in a real‐world inflammatory bowel disease cohort Open
Background Switching from originator infliximab (IFX) to biosimilar IFX is effective and safe. However, data on multiple switching are scarce. The Edinburgh inflammatory bowel disease (IBD) unit has undertaken three switch programmes: (1) …
View article: P127 Inflammatory Bowel Disease-associated colorectal cancers: retrospective cohort study from a tertiary centre surveillance programme over 10 years
P127 Inflammatory Bowel Disease-associated colorectal cancers: retrospective cohort study from a tertiary centre surveillance programme over 10 years Open
Background Patients with IBD have increased risk for developing colorectal cancer (CRC), with poorer survival, compared to those without IBD. Despite surveillance colonoscopy, IBD post-colonoscopy CRC (PCCRC) rates are unacceptably high at…
View article: P557 Analysis of colectomy rates and advanced therapy prescribing for ulcerative colitis in Lothian; Scotland an updated population based cohort study
P557 Analysis of colectomy rates and advanced therapy prescribing for ulcerative colitis in Lothian; Scotland an updated population based cohort study Open
Background The impact of advanced therapies on colectomy rates in UC remains unclear. We have published a population-based cohort reporting patterns of advanced therapy prescribing and the impact on colectomy rates complete to 2018 The aim…
View article: P509 Surgery and biologic prescription rates for Crohn's disease in Lothian, Scotland; an updated population-based cohort study.
P509 Surgery and biologic prescription rates for Crohn's disease in Lothian, Scotland; an updated population-based cohort study. Open
Background Recent years have seen a shift in Crohn’s disease (CD) management to earlier initiation of biologic therapy using a treat to target strategy. We have previously published a population based cohort showing a reduction in CD surge…
View article: P745 Multiple infliximab biosimilar switches appear to be safe and effective in a real-world inflammatory bowel disease cohort
P745 Multiple infliximab biosimilar switches appear to be safe and effective in a real-world inflammatory bowel disease cohort Open
Background Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT…
View article: Rates, predictive factors and effectiveness of ustekinumab intensification to 4- or 6-weekly intervals in Crohn's disease
Rates, predictive factors and effectiveness of ustekinumab intensification to 4- or 6-weekly intervals in Crohn's disease Open
One third of CD patients treated with UST underwent dose intensification to a 4- or 6-weekly interval within the first year. Patients who failed both anti-TNF and vedolizumab, or required steroids at initiation were more likely to dose int…
View article: Longitudinal Faecal Calprotectin Profiles Characterise Disease Course Heterogeneity in Crohn’s Disease
Longitudinal Faecal Calprotectin Profiles Characterise Disease Course Heterogeneity in Crohn’s Disease Open
A bstract Background and Aims The progressive nature of Crohn’s disease is highly variable and hard to predict. In addition, symptoms correlate poorly with mucosal inflammation. There is therefore an urgent need to better characterise the …
View article: Patterns of emergency admission for IBD patients over the last 10 years in Lothian, Scotland: a retrospective prevalent cohort analysis
Patterns of emergency admission for IBD patients over the last 10 years in Lothian, Scotland: a retrospective prevalent cohort analysis Open
Summary Objective It is unclear how the compounding prevalence of inflammatory bowel disease (IBD) has translated into the causes and rates of hospitalisation, particularly in an era of increased biologic prescribing. We aimed to analyse t…
View article: P579 Rates, predictive factors and effectiveness of ustekinumab intensification to 4- or 6-weekly intervals in Crohns’s disease
P579 Rates, predictive factors and effectiveness of ustekinumab intensification to 4- or 6-weekly intervals in Crohns’s disease Open
Background The efficacy and safety of ustekinumab (UST) intravenous induction followed by 8- and 12- weekly maintenance was established in the UNITI controlled trial. These data report dose intensification for 12- to 8-weekly but not 4-wee…
View article: P489 Temporal trends of colectomy for ulcerative colitis in the multi-drug era; a population based cohort study
P489 Temporal trends of colectomy for ulcerative colitis in the multi-drug era; a population based cohort study Open
Background We are now in the multi-drug era for ulcerative colitis (UC). The use of advanced therapies for UC has dramatically increased over the last 6 years. NICE approvals of anti-TNF and anti-α4β7 therapy (both in 2015) were followed b…
View article: PMO-48 Both single and multiple switching between infliximab biosimilars can be safe and effective in ibd
PMO-48 Both single and multiple switching between infliximab biosimilars can be safe and effective in ibd Open
Introduction There is extensive data on the safety and effectiveness of switching from originator infliximab to biosimilar infliximab. However, there is relatively little data regarding biosimilar-biosimilar infliximab switch nor on multip…
View article: PMO-49 Patient perceptions about causes of flare in IBD: baseline results from the PREdiCCt study
PMO-49 Patient perceptions about causes of flare in IBD: baseline results from the PREdiCCt study Open
Introduction Patient reported outcomes are important endpoints in Inflammatory Bowel Disease (IBD) management, but patient perceptions of the causes of disease flare are unknown and thus may reveal novel areas for future study. Methods The…